MarketLens
Sign Up

Is Collegium Pharmaceutical's Diversification Strategy Paying Off

7 months ago
SHARE THIS ON:

Is Collegium Pharmaceutical's Diversification Strategy Paying Off

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 day ago

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

Ionis Pharmaceuticals is shifting toward independent launches to capture more commercial upside, while partner royalties and new drugs TRYNGOLZA, DAWNZERA, ZANVASTRO, and HIBSAGO broaden revenue and p...
Stock News•1 months ago

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?

Bristol Myers Squibb's growth portfolio is gaining ground as newer drugs offset mature-product declines, reshaping its revenue mix. The shift could stabilize overall sales if new launches keep scaling...
Stock News•2 months ago

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical is shifting to a CNS platform, using stable pain cash flows to fund ADHD growth. The $350M cash and $300M debt AZSTARYS acquisition is expected to add $60–70M revenue in 2026 ...

Breaking News

View All →

Top Headlines

View More →
Stock News•20 minutes ago

GOOGL, GOOG Investors Have Opportunity to Lead Alphabet Inc. Securities Fraud Lawsuit

Stock News•1 hour ago

CrowdStrike Holdings (CRWD) Laps the Stock Market: Here's Why

Stock News•1 hour ago

Nvidia (NVDA) Surpasses Market Returns: Some Facts Worth Knowing

Stock News•1 hour ago

Apple (AAPL) Stock Falls Amid Market Uptick: What Investors Need to Know

Stock News•1 hour ago

Palo Alto Networks (PANW) Laps the Stock Market: Here's Why